And patients with gastric or esophageal adenocarcinoma would have a much better prognosis after treating with neoadjuvant ± adjuvant fluoropyrimidine– and oxaliplantin-based chemotherapy, if the expression level of PODXL is high [50]. This evidence concerns the gene PODXL and esophageal adenocarcinoma.